Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $660.27M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.18M
Average 0.08M
NVCT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Nuvectis Pharma, Inc.NASDAQ: NVCT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$6.05M, compared with -$5.33M a year earlier. Trailing-twelve-month EBITDA was -$28.06M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -39.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.05M+26.3% QoQ
- Last fiscal yearDec 2025
- -$26.44M-39.2% YoY
- LTMMar 2026
- -$28.06M-39.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.5% | +100.0% | +113.5 pp |
| 1 year | -39.2% | +100.0% | +139.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (26.44M) USD
- Year-over-year change
- -39.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.44M) | -39.2% |
| FY2024 | 2024-12-31 | (19M) | +14.6% |
| FY2023 | 2023-12-31 | (22.26M) | -16.6% |
| FY2022 | 2022-12-31 | (19.09M) | -48.1% |
| FY2021 | 2021-12-31 | (12.89M) | — |
EBITDA vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's LTM Mar 2026 EBITDA of -$28.06M is the highest of the 11 companies compared; the peer median is -$89.75M.
- Its year-over-year change of -39.2% is the 9th highest of 11, against a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$28.06M | -39.2% | — | — | |
| LTM Mar 2026 | -$34.56M | -66.8% | — | — | |
| LTM Mar 2026 | -$39.29M | +13.4% | — | 7858.4% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
| LTM Mar 2026 | -$162.5M | +50.0% | — | 74.8% | |
| LTM Mar 2026 | -$191.95M | -32.3% | — | 387.1% | |
| Peer median (excluding NVCT) | -$89.75M | -4.4% | — | 231.0% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 9.55M | 13.23M | 15.38M | 12.92M | 18.15M |
| Selling, General & Admin | 3.35M | 6.01M | 7.52M | 6.93M | 9.42M |
| Operating Expenses | 12.89M | 19.23M | 22.9M | 19.85M | 27.57M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (12.89M) | (19.23M) | (22.9M) | (19.85M) | (27.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 4K | 149K | 637K | 847K | 1.13M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4K | 149K | 637K | 847K | 1.13M |
| Income Before Tax | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.89M) | (19.09M) | (22.26M) | (19M) | (26.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| EPS (Diluted) | (1.09) | (1.51) | (1.43) | (1.11) | (1.32) |
| Weighted Avg Shares | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
| Weighted Avg Shares (Diluted) | 12.72M | 12.66M | 15.56M | 17.11M | 21.81M |
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$19.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.